Expert Ratings For DexCom
Portfolio Pulse from Benzinga Insights
Over the past three months, 6 analysts have provided ratings for DexCom (NASDAQ:DXCM), with recent updates showing a positive trend in sentiment and an increase in the 12-month price target to an average of $134.5, up from $120.33. Analysts from firms such as Raymond James, Piper Sandler, Wells Fargo, and Morgan Stanley have raised their price targets, reflecting optimism about DexCom's financial health, which includes strong revenue growth, net margin, ROE, and ROA, despite some concerns over debt management.
January 23, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have raised their price targets for DexCom, indicating a bullish sentiment. The company's strong financial performance, including revenue growth and profitability, supports these positive ratings, although debt levels remain a concern.
The unanimous positive revisions in analyst ratings and price targets for DexCom suggest a strong consensus about the company's growth prospects and market position. The increased average price target reflects heightened expectations for the stock's performance. However, the high debt-to-equity ratio introduces some caution, which might temper the stock's upward momentum. Overall, the positive outlook from analysts is likely to have a favorable impact on the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100